Non-invasive ventilation

$23.1 Billion Sleep Apnea Devices Market, Industry Trends and Global Forecasts 2024-2035 - ResearchAndMarkets.com

Retrieved on:

星期二, 五月 14, 2024

The growth in the sleep apnea devices market share over the next decade is likely to be the result of anticipated increase in patient population and rise in the demand for sleep apnea devices for sleep apnea treatment.

Key Points:

The growth in the sleep apnea devices market share over the next decade is likely to be the result of anticipated increase in patient population and rise in the demand for sleep apnea devices for sleep apnea treatment.
The global sleep apnea diagnostic devices market is categorized into polysomnography devices and home sleep apnea testing devices.
The market report features an extensive study of the current market landscape, sleep apnea devices market share, market size, market analysis, market forecast and future opportunities for the sleep apnea companies involved in the development of sleep apnea medical devices and sleep apnea drugs.
Sleep Apnea Devices Market Analysis: Sleep Apnea Therapeutic Devices Hold Majority Market Share
The global sleep apnea devices market is estimated to be worth USD 13.5 billion in 2024.

Philips Respironics reaches agreement with US government on a consent decree creating a clear path forward

Retrieved on:

星期三, 四月 10, 2024

FDA, Patient safety, Respironics, Food, EUR, Quality, PHG, Mask, Patient, DOJ, AEX, Adjustment, Non-invasive ventilation, Sleep, CPAP, Medical device

Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA and Philips Respironics have now reached final agreement on the consent decree with the DOJ and FDA.

Key Points:

Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA and Philips Respironics have now reached final agreement on the consent decree with the DOJ and FDA.
As previously stated:
The consent decree primarily focuses on Philips Respironics’ business operations in the US.
It provides clarity and a roadmap to demonstrate compliance with regulatory requirements and to restore the Philips Respironics business.
Philips Respironics is committed to meeting the consent decree requirements, while continuing to service healthcare providers and their patients under agreed conditions in the US and outside the US.

FDA Announces Federal Court Enters Consent Decree Against Philips Respironics Following Recall of Certain Sleep Therapy Machines

Retrieved on:

星期二, 四月 9, 2024

SILVER SPRING, Md., April 9, 2024 /PRNewswire/ -- Today, the U.S. District Court for the Western District of Pennsylvania entered a consent decree of permanent injunction against Philips RS North America LLC ("Philips Respironics"), Respironics California LLC, and Philips Holding USA Inc., and Roy Jakobs, CEO of Royal Philips, along with several other individual defendants named in the decree. The consent decree, with limited exceptions, restricts the production and sale of new continuous positive airway pressure (CPAP) machines, bi-level positive airway pressure (BiPAP) machines and other devices at several Philips Respironics facilities in the United States until certain requirements are met. CPAP and BiPAP machines are sleep therapy devices used for the treatment of obstructive sleep apnea. The decree also requires implementation of a Recall Remediation Plan, agreed to by the FDA and Philips Respironics, to help ensure relief is provided to patients impacted by Philips Respironics' June 2021 recall of certain ventilators, CPAP and BiPAP machines, by way of receiving a new or reworked/remediated device or, for certain devices, providing the option for a partial refund.

Key Points:

The consent decree , with limited exceptions, restricts the production and sale of new continuous positive airway pressure (CPAP) machines, bi-level positive airway pressure (BiPAP) machines and other devices at several Philips Respironics facilities in the United States until certain requirements are met.
CPAP and BiPAP machines are sleep therapy devices used for the treatment of obstructive sleep apnea.
This also marks the first time a device company is providing a remediation payment option for a recalled device under a consent decree."
The consent decree comes after Philips Respironics recalled certain ventilators, CPAP and BiPAP machines in June 2021 because of potential health risks—impacting 15 million devices worldwide.

Sleep Apnea Devices Market, Industry Trends and Global Forecasts, 2035

Retrieved on:

星期五, 三月 15, 2024

The growth in the sleep apnea devices market share over the next decade is likely to be the result of anticipated increase in patient population and rise in the demand for sleep apnea devices for sleep apnea treatment.

Key Points:

The growth in the sleep apnea devices market share over the next decade is likely to be the result of anticipated increase in patient population and rise in the demand for sleep apnea devices for sleep apnea treatment.
The global sleep apnea diagnostic devices market is categorized into polysomnography devices and home sleep apnea testing devices.
The market report features an extensive study of the current market landscape, sleep apnea devices market share, market size, market analysis, market forecast and future opportunities for the sleep apnea companies involved in the development of sleep apnea medical devices and sleep apnea drugs.
Sleep Apnea Devices Market Analysis: Sleep Apnea Therapeutic Devices Hold Majority Market Share
The global sleep apnea devices market is estimated to be worth USD 13.5 billion in 2024.

REMSleep Holdings Shareholder Update

Retrieved on:

星期一, 三月 4, 2024

CLEARWATER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - REMSleep Holdings, Inc. (OTC PINK: RMSL) gives an update on FDA process and REMSleep status.

Key Points:

CLEARWATER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - REMSleep Holdings, Inc. (OTC PINK: RMSL) gives an update on FDA process and REMSleep status.
We have had numerous inquiries asking for REMSleep regulatory status update.
REMSleep consultants are confident we will receive our 510(K) and we will never give up until we are successful.
REMSleep has addressed this problem by developing a novel CPAP nasal pillow interface that has been engineered to reduce pressure and enable better airflow.

Philips delivers strong full-year results; agrees with FDA on terms of consent decree focused on Philips Respironics in the US

Retrieved on:

星期一, 一月 29, 2024

1) Excluding provisions charged to sales of EUR 174 million in Q4 2023 mainly in connection with the Respironics consent decree.

Key Points:

1) Excluding provisions charged to sales of EUR 174 million in Q4 2023 mainly in connection with the Respironics consent decree.
We are fully committed to complying with the consent decree, which is an important step and provides a clear path forward.
The consent decree primarily focuses on Philips Respironics’ business operations in the US.
*) Excluding provisions charged to sales of EUR 174 million in Q4 2023 mainly in connection with the Respironics consent decree.

Settlement Administrator Angeion Group Announces Proposed Settlement in In Re Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Litigation Class Action

Retrieved on:

星期四, 一月 11, 2024

Notice, Non-invasive ventilation, Device, Documentation, Payment, User, Respironics, Settlement, BIPAP, Grant Street, Court, CPAP, Ventilator, Joseph, Vexatious litigation, Hearing, Motion, Service award, Health insurance

PHILADELPHIA, Jan. 11, 2024 /PRNewswire/ -- A proposed Settlement of Economic Loss Claims has been reached in a U.S. class action lawsuit against Defendants Philips RS North America LLC ("Philips RS"), Koninklijke Philips N.V., Philips North America LLC, Philips Holding USA, Inc., and Philips RS North America Holding Corporation (collectively, the "Philips Defendants"), related to CPAP, BiPAP and ventilator devices sold in the United States between 2008 and 2021 that Philips RS recalled beginning in June 2021. Plaintiffs in this lawsuit allege that the particular type of noise-reducing foam used in the recalled devices was defective. The Settlement is intended to resolve Economic Loss Claims only and does not affect or release any claims for personal injuries or medical monitoring relief.

Key Points:

If You Paid For A Philips CPAP, BIPAP, Or Ventilator That Was Recalled By Philips RS North America LLC Beginning in June 2021, A Class Action Settlement May Affect Your Legal Rights.
Plaintiffs in this lawsuit allege that the particular type of noise-reducing foam used in the recalled devices was defective.
The Settlement is intended to resolve Economic Loss Claims only and does not affect or release any claims for personal injuries or medical monitoring relief.
You may be eligible to receive a payment if you paid for a Philips Respironics CPAP, BiPAP, or Ventilator that was recalled.

Settlement Administrator Angeion Group Announces Proposed Settlement in In Re Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Litigation Class Action

Retrieved on:

星期一, 十二月 11, 2023

PHILADELPHIA, Dec. 11, 2023 /PRNewswire/ -- A proposed Settlement of Economic Loss Claims has been reached in a U.S. class action lawsuit against Defendants Philips RS North America LLC ("Philips RS"), Koninklijke Philips N.V., Philips North America LLC, Philips Holding USA, Inc., and Philips RS North America Holding Corporation (collectively, the "Philips Defendants"), related to CPAP, BiPAP and ventilator devices sold in the United States between 2008 and 2021 that Philips RS recalled beginning in June 2021. Plaintiffs in this lawsuit allege that the particular type of noise-reducing foam used in the recalled devices was defective. The Settlement is intended to resolve Economic Loss Claims only and does not affect or release any claims for personal injuries or medical monitoring relief.

Key Points:

If You Paid For A Philips CPAP, BIPAP, Or Ventilator That Was Recalled By Philips RS North America LLC Beginning in June 2021, A Class Action Settlement May Affect Your Legal Rights.
Plaintiffs in this lawsuit allege that the particular type of noise-reducing foam used in the recalled devices was defective.
The Settlement is intended to resolve Economic Loss Claims only and does not affect or release any claims for personal injuries or medical monitoring relief.
You may be eligible to receive a payment if you paid for a Philips Respironics CPAP, BiPAP, or Ventilator that was recalled.

Settlement Administrator Angeion Group Announces Proposed Settlement in In Re Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Litigation Class Action

Retrieved on:

星期一, 十二月 11, 2023

PHILADELPHIA, Dec. 11, 2023 /PRNewswire/ -- A proposed Settlement of Economic Loss Claims has been reached in a U.S. class action lawsuit against Defendants Philips RS North America LLC ("Philips RS"), Koninklijke Philips N.V., Philips North America LLC, Philips Holding USA, Inc., and Philips RS North America Holding Corporation (collectively, the "Philips Defendants"), related to CPAP, BiPAP and ventilator devices sold in the United States between 2008 and 2021 that Philips RS recalled beginning in June 2021. Plaintiffs in this lawsuit allege that the particular type of noise-reducing foam used in the recalled devices was defective. The Settlement is intended to resolve Economic Loss Claims only and does not affect or release any claims for personal injuries or medical monitoring relief.

Key Points:

If You Paid For A Philips CPAP, BIPAP, Or Ventilator That Was Recalled By Philips RS North America LLC Beginning in June 2021, A Class Action Settlement May Affect Your Legal Rights.
Plaintiffs in this lawsuit allege that the particular type of noise-reducing foam used in the recalled devices was defective.
The Settlement is intended to resolve Economic Loss Claims only and does not affect or release any claims for personal injuries or medical monitoring relief.
You may be eligible to receive a payment if you paid for a Philips Respironics CPAP, BiPAP, or Ventilator that was recalled.

Exploring Parkinson's Disease Statistics: Market Insight, Epidemiology ,Forecast Price and Market Access ,Commercial Strategy Analysis, Drug Development & Healthcare Consulting Services by Disease landscape Insights

Retrieved on:

星期四, 九月 14, 2023

Advancements in Parkinson's Disease Diagnosis: Facilitating Patient Care

Key Points:

Advancements in Parkinson's Disease Diagnosis: Facilitating Patient Care
Parkinson's Disease can be challenging to diagnose, often leading to delayed treatment initiation.
However, recent advancements in diagnostic tools have empowered healthcare professionals to identify the disease more accurately and at earlier stages.
DiseaseLandscape Insights is at the forefront of drug insights and discovery, product launches, and clinical trial feasibility analysis in the fight against Parkinson's Disease.
The Parkinson's Disease Overview by healthcare consulting services provider DLI shows that it is competitive, with pharmaceutical companies vying to develop better treatments.